Company intelligence / Profile preview

Abalone Bio

Ownership: Private
Employees: ~12
Development stage: Preclinical

Overview

Abalone Bio has developed anti-inflammatory candidates that treat neuropathic pain and fibrosis in animal models and in human tissue samples. They have also uncovered activator antibodies for pharmaceutical partners.

Therapeutic areas: GastroenterologyMetabolic DisordersNephrologyEndocrinologyImmunologyOncologyNeurology
Modalities: Antibody drugsNanobodiesVHH-Fc fusion antibodies
Industry: Biotech

Partnerships

University of PennsylvaniaUnnamed pharmaceutical partners

Beyond the preview

Go deeper on Abalone Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Abalone Bio.

Explore the full profile